Hypertension: How should data from SYMPLICITY HTN-3 be interpreted?

Nature Reviews Cardiology

Volumn 11, Issue 7, 2014, Pages 375-376

  Schmieder, Roland E ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN;

ADRENERGIC SYSTEM; AFRICAN AMERICAN; ARTICLE; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; HAWTHORNE EFFECT; HUMAN; INTRAVASCULAR CATHETER; KIDNEY DENERVATION; MEDICATION COMPLIANCE; MORTALITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE;

AFRICAN AMERICANS; HUMANS; HYPERTENSION; KIDNEY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84903277665     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.70     Document Type: Article

References (10)

1. Bangalore, S. et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am. J. Med. 127, 71-81.e1 (2014).
2. Mancia, G. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31, 1281-1357 (2013).
3. Bhatt, D. L. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370, 1393-1401 (2014).
4. Krum, H. for the Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57, 911-917 (2011).
5. Esler, M. D. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 376, 1903-1909 (2010).
6. Mahfoud, F. et al. Reduction in office blood pressure after renal denervation in a large real world patient population with uncontrolled hypertension: interim results from the global SYMPLICITY registry. Presented at the 2014 ACC Scientific Sessions.
7. O'Brien, E. et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J. Hypertens. 31, 1731-1768 (2013).
8. Weber, M. A. et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374, 1423-1431 (2009).
9. Oxlund, C. S. et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J. Hypertens. 31, 2094-2102 (2013).
10. Mahfoud, F. et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 128, 132-140 (2013).